The global glycosylated peptide market is expected to grow at a significant CAGR during the forecast period. Peptide drugs are potential therapeutic agents. Additionally, glycosylation of peptides is a strategy that modulates the physicochemical properties of peptide drugs. Further, it also penetrates peptides across biological membranes as well as enhances bioactivity, selectivity and prolong the half-life of the therapeutic drug. Moreover, there are two types of glycosylation of peptides including N-linked glycosylation or O-linked glycosylation.  The major factor owing to the growth of the market is glycosylated peptide being a key biological function with unique intrinsic properties with the potential to treat a variety of diseases. Moreover, it has key benefits such as better solubility, improved response to the therapy, and provides extended dosing duration. These key benefits of the glycosylated peptides show high biological activity and the availability of innovative peptides in the market is driving the market growth during the forecast period. 

Impact of COVID-19 Pandemic on the Global Glycosylated Peptide Market

The COVID-19 pandemic has impacted the global economy due to a slowdown owing to the nationwide lockdown by several governments globally. The COVID-19 pandemic has caused enormous challenges in healthcare and pharmaceuticals globally. Furthermore, the COVID-19 pandemic has impacted practically every industry and also the global glycosylated peptide market, due to impact on trade segment, manufacturing, and closing the industry due to lockdown. However, as the COVID-19 situation normalizes, the global glycosylated peptide market started recovery as industrial operations were normalized after the recovery. 

Segmental Outlook 

The global glycosylated peptide market is segmented based on type and application. Based on the type, the market is segmented into Monoclonal Antibodies (MABs), Erythropoietin (EPO), and others. Based on the application, the market is sub-segmented into Oncology, Blood Disorder, and Others. Among these, Monoclonal Antibodies (MABs) are going to lead the global glycosylated peptide market in the type segment. Furthermore, Oncology and Blood Disorder is going to lead the global glycosylated peptide market in the application segment.

Global Glycosylated Peptide Market Share by Type, 2021 (%)

The Monoclonal Antibodies (MABs) are Holding a Prominent Share in the Global Glycosylated Peptide Market

Monoclonal Antibodies is holding the largest share in the market owing to their treatments that enlist the body’s germ-fighting immune system against diseases including cancer. Furthermore, it is designed to function in different ways to treat diseases. These functions include flagging cancer cells, triggering cell-membrane destruction, blocking cell growth, preventing blood vessel growth, blocking immune system inhibitors, directly attacking cancer cells, delivering radiation treatment, delivering chemotherapy, and binding cancer and immune cells.

Regional Outlooks

Glycosylated Peptide Market is further segmented on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). The North American region dominates the market, followed by Europe as the second-largest market for glycosylated peptides. In addition, the Asia Pacific is expected to witness significant growth during the forecast period.

Global Glycosylated Peptide Market Growth, by region 2022-2028 

North America region is estimated to Hold a Prominent Share in the Global Glycosylated Peptide Market

North America is anticipated to hold a prominent share in the market owing to the ongoing research and development in the region. Further, the advanced technologies developed and accepted by the market players in this region coupled with the presence of advanced treatment of the diseases in comparison with other regions. Moreover, increasing Food and Drug Administration (FDA) approved products in the region will also boost the growth of the glycosylated peptide market.

Market Players Outlook

The major companies serving the global Glycosylated Peptide Market include Bachem Group, Biocon Ltd., Celltrion Healthcare Co. Ltd., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., and Others. The growth of the market is considerably contributed by the market player for the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2022, Sterling Pharma Solutions announced that it will acquire a former Novartis facility in Ringaskiddy, Ireland. The acquisition will boost the sterling’s small-molecule API production while also extending its capabilities in technologies such as peptide manufacturing and large-scale chromatography.

The Report Covers

• Market value data analysis of 2022 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Glycosylated Peptide Market. Based on the availability of data, information related to the market, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.